Dash Bio
Ely Porter currently serves as the Chief Scientific Officer at Dash Bio, a position held since October 2024. Previously, Porter was a Chief Technology Officer and Co-founder of RootPath from May 2017 to May 2023, and a Co-Founder and VP of Technology during the same time frame. In addition, Porter worked at Nest.Bio Ventures as a team member from May 2017 to March 2020. Academic experience includes a role as a Postdoctoral Associate and Ragon Fellow at the Massachusetts Institute of Technology (MIT) from August 2015 to May 2017, focusing on the development of small molecule induced regulatory mechanisms for RNA-only gene circuits. Ely Porter earned a Ph.D. in Biochemistry from the University of Colorado Boulder and a B.S. in Biology from The Ohio State University.
This person is not in any teams
This person is not in any offices
Dash Bio
At Dash Bio, we're revolutionizing clinical bioanalysis to expedite drug development. By leveraging AI and robotics, we deliver higher-quality assays with turnaround times up to 10x faster than the industry average for clinical trials and GLP studies. While AI startups have transformed drug discovery, the development phase remains bogged down by manual, labor-intensive processes. We're changing that narrative. Our tech-first products automate critical steps, reducing costs and time to market without compromising on quality. Our initial product line focuses on clinical bioanalysis—the testing of samples from clinical trial subjects. With a fresh perspective, we've built a modern platform where quality, automation, and regulation work seamlessly together. Why settle for traditional methods when you can invest in results? We're obsessed with enhancing customer experience and outcomes, constantly pushing boundaries to make processes better and faster. Meet Our Leadership Team: Dave Johnson, CEO: Former Chief Data and AI Officer at Moderna. Ander Tallett, COO: Led Enterprise Systems at Moderna and Resilience. Ely Porter, CSO: Co-founder and CTO of Rootpath. Together, we're crafting a future where bioanalysis is intuitive, data flows effortlessly, and drugs reach the market faster than ever before. Join us on this journey. Learn more at dash.bio